Ads
related to: sarcoma cancer- Causes of Sarcoma
Access a Sarcoma Treatment Guide.
Learn About the Causes of Sarcoma.
- Sarcoma Second Opinions
In Need of a Second Opinion?
Our Cancer Answer Line Can Help.
- Sarcoma Treatment Options
Access a Sarcoma Treatment Guide.
Understand Your Treatment Options.
- Schedule an Appointment
Schedule an Appointment Today.
Call Our Cancer Answer Line.
- Causes of Sarcoma
Search results
Douglas W. Priebe
Chicago Tribune· 6 days agoDouglas W. Priebe, 59, passed away peacefully on May 8, 2024 in Libertyville, IL with his sister, Susan, by his side. Doug was born on April 28, 1965 and was a lifelong resident of Libertyville ...
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 7 days agoExplore key insights from TRACON Pharmaceuticals' Q1 2024 earnings, focusing on financial improvements, trial progress, and strategic maneuvers to maintain NASDAQ compliance.
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 15 hours agoSanta Barbara, CA, May 21, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its ...
Gut bacteria boost immune response to fight tumors | Newswise
Newswise· 7 days agoRoughly one in five cancer patients benefits from immunotherapy – a treatment that harnesses the immune system to fight cancer. Such an approach to beating cancer has seen significant success ...
Adaptimmune Therapeutics (NASDAQ:ADAP) PT Lowered to $3.00 at Mizuho
ETF DAILY NEWS· 5 days agoAdaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price target cut by research analysts at Mizuho from $9.00 to $3.00 in a research report issued on Friday, Benzinga reports.
HC Wainwright Reaffirms Buy Rating for BioAtla (NASDAQ:BCAB)
ETF DAILY NEWS· 4 days agoHC Wainwright restated their buy rating on shares of BioAtla (NASDAQ:BCAB – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $7.00 price target ...
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights
Guru Focus· 7 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. BioAtla Inc (BCAB, Financial) reported encouraging data readouts for CAB-ROR2 ADC in treatment-refractory ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 7 days agoIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress PR Newswire HOUSTON, May 16, 2024 HOUSTON, May 16, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or
Ad
related to: sarcoma cancer
